drugset / Trial / NCT05547243
A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China
Unknown
350 enrolled
AIM Vaccine Co., Ltd.
Ningbo Rongan Biological Pharmaceutical Co., Ltd. · collabThe First Affiliated Hospital of Bengbu Medical University · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
This is a cohort study to evaluate safety and immunogenicity of COVID-19 mRNA Vaccine, Bivalent (LVRNA021) in participants aged 18 years and over in China
Timeline
- Start
- 2022-09-26
- Primary completion
- 2022-12-23
- Completion
- 2024-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LVRNA021 | Messenger RNA (mRNA) | 50 ug | Intramuscular |
| Subject | LVRNA021 | Messenger RNA (mRNA) | 100 ug | Intramuscular |